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Abstract
Previously, it was demonstrated that immunoliposomes, bearing anti-intercellular adhesion molecule-1 (ICAM-1)
antibodies (mAb F10.2), can specifically bind to different cell types expressing ICAM-1. In this study, we have quantified the
amount of immunoliposomes binding to IFN-Q activated human bronchial epithelial cells (BEAS-2B) in vitro and studied the
subsequent fate of cell-bound anti-ICAM-1 immunoliposomes. We demonstrate that binding of the immunoliposomes to the
epithelial cells depends on the liposome concentration used. After binding to the cell surface, the anti-ICAM-1
immunoliposomes are rapidly internalised by the epithelial cells. Sixty percent of cell-bound immunoliposomes were
internalised by the epithelial cells within 1 h of incubation at 37‡C. The results indicate that ICAM-1 targeted
immunoliposomes may be used as carriers for the intracellular delivery of anti-inflammatory drugs to sites of inflammation
characterised by an increased expression of ICAM-1. ß 1999 Elsevier Science B.V. All rights reserved.
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1. Introduction
Adhesion molecules are cell surface glycoproteins
that mediate physical and functional interactions be-
tween two cells or between cells and their extracellu-
lar matrix. They play an important role in many bio-
logical processes as diverse as the complex
organisation of tissues and organs, the migration of
cells during embryogenesis and the regulation of im-
mune responses by mediating the communication be-
tween di¡erent immune cells and the extravasation of
in£ammatory cells into in£amed tissues [1^3]. The
process of leukocyte extravasation is induced by the
local release of pro-in£ammatory mediators (vasoac-
tive amines and cytokines) at the site of in£amma-
tion. This results in a locally induced or increased
expression of a variety of adhesion molecules on en-
dothelial cells, which allows multiple adhesive events
with circulating leukocytes to occur.
Intercellular adhesion molecule-1 (ICAM-1) is an
important adhesion molecule involved in the process
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of leukocyte adhesion and extravasation. ICAM-1 is
an immunoglobulin-like transmembrane glycoprotein
that is constitutively expressed at low levels on vas-
cular endothelial cells, epithelial cells and on a subset
of leukocytes and its expression is increased by the
pro-in£ammatory cytokines interferon-Q (IFN-Q), tu-
mour necrosis factor K (TNF-K) or interleukin-1 (IL-
1) [4^9]. Numerous studies have demonstrated a lo-
cally enhanced ICAM-1 expression in in£ammation-
related diseases, such as rheumatoid arthritis [10],
asthma [11,12], nephritis [13,14], in£ammatory der-
matosis [15,16], and atherosclerosis [17,18]. The in-
creased expression of ICAM-1 and other cell adhe-
sion molecules at sites of in£ammation is under
investigation for therapeutic intervention. Up-regu-
lated expression of adhesion molecules may be uti-
lised as targets for drug carrier systems for selective
delivery of anti-in£ammatory compounds to sites of
in£ammation. In this light, we have previously con-
structed liposomes bearing antibodies to ICAM-1
[19]. These antibody-containing liposomes (immuno-
liposomes) were shown to strongly bind to di¡erent
cell types expressing ICAM-1 on their surface and
their binding was positively correlated with the ex-
pression level of ICAM-1 on the target cells. After
this ¢rst report on immunoliposome targeting to cells
expressing adhesion molecules, two other reports
have appeared con¢rming this possibility [20,21].
Speci¢c binding of immunoliposomes to their tar-
get cells is an important prerequisite to ful¢l but on
its own not enough for e¡ective drug delivery. As
many drugs act at intracellular sites, it is required
that immunoliposome-encapsulated drugs are deliv-
ered intracellularly. In principle, three routes that
may lead to intracellular delivery of encapsulated
compounds can be discerned. Firstly, immunolipo-
somes may, after speci¢c cell binding, release their
contents in close proximity of the target cells, with
subsequent cellular uptake of released molecules.
Secondly, immunoliposomes may fuse with the cell
membrane, thereby releasing their contents into the
cytosol. Thirdly, cell-bound immunoliposomes may
be internalised by the target cells via receptor-medi-
ated endocytosis, followed by the intracellular release
of encapsulated agents. Whether immunoliposomes
will be internalised or not is dependent on a variety
of factors, such as liposome size [22^25], type of cell
and type of target receptor [26^28]. Targeting of im-
munoliposomes to receptors with known internalis-
ing capacities (e.g. transferrin receptor, low density
lipoprotein-receptor, epithelial growth factor recep-
tor) will likely result in internalisation of bound im-
munoliposomes, provided that they are relatively
small in size (6 0.2 Wm) [29^31]. On the other
hand, it has been shown that immunoliposomes tar-
geted to non-internalising cell surface molecules on
tumour cells remain located at the cell surface [32].
Here, we report on the interaction of ICAM-1-di-
rected immunoliposomes with ICAM-1 expressing
human bronchial epithelial cells in vitro. We have
quanti¢ed the degree of cell binding of ICAM-1-di-
rected liposomes and we demonstrate that speci¢c
binding of these immunoliposomes to ICAM-1 on
the bronchial epithelial cell line BEAS-2B triggers
rapid internalisation of cell-bound immunolipo-
somes. The results are discussed in the context of
targeted drug delivery to sites of in£ammation, char-
acterised by an increased expression of ICAM-1.




thioacetate (SATA), N-ethylmaleimide, and calcein
were obtained from Sigma (Rockford, IL, USA).
Chloroform and methanol (pro analysi) were ob-
tained from Merck (Darmstadt, Germany), and
N,N-dimethylformamide (DMF) and hydroxylamine
hydrochloride from Janssen Chimica (Geel, Bel-
gium). Partially hydrogenated egg phosphatidylcho-
line with an iodine value of 40 (PHEPC; Asahi, Ibar-
akiken, Japan) was prepared as described previously
[33]. Egg phosphatidylglycerol (EPG) was kindly do-
nated by Nattermann (Cologne, Germany), N-[4-(p-
maleimidophenyl) butyryl]phosphatidylethanolamine
(MPB-PE) was synthesised as described before
[32,34].
2.1.2. Cell-related materials
IFN-Q was purchased from Boehringer-Mannheim
(Mannheim, Germany), keratinocyte medium (kera-
tinocyte-SFM) and supplements for keratinocyte-
SFM, containing recombinant human epithelial
BBAMEM 77626 7-7-99 Cyaan Magenta Geel Zwart
E. Mastrobattista et al. / Biochimica et Biophysica Acta 1419 (1999) 353^363354
growth factor (rhEGF), and bovine pituitary extract
came from Gibco, Grand Island, NY, USA. Bovine
serum albumin (fraction V), £uorescein isothiocya-
nate (FITC)-labelled goat anti-mouse F10.2 IgG
(FabP-speci¢c) and R-phycoerythrin (PE)-labelled
goat anti-mouse IgG were obtained from Sigma.
Anti-ICAM-1 mAb (IgG1), clone F10.2 was pre-
pared and isolated as described before [35]. Form-
aldehyde was obtained from Janssen (Geel, Bel-
gium).
2.2. Cell culture
The human bronchial epithelial cell line BEAS-2B
obtained from Dr J.F. Lechner (National Institutes
of Health, Bethesda, MD, USA) was cultured in se-
rum-free keratinocyte medium, supplemented with
bovine pituitary extract (25 Wg/ml), rhEGF (2.5 ng/
ml) and gentamicin (50 Wg/ml). In order to obtain an
enhanced expression of ICAM-1, BEAS-2B cells
were stimulated with IFN-Q (200 U/ml) 24 h prior
to use in immunoliposomes binding and internalisa-
tion experiments [7]. BEAS-2B cells were cultured at
37‡C with 5% CO2 in humidi¢ed air.
2.3. Preparation of immunoliposomes
Immunoliposomes, bearing covalently coupled
F10.2 mAbs on their surface, were prepared as de-
scribed previously [19]. In short, liposomes were
made from PHEPC, EPG, CHOL, and MPB-PE
(38.5:4:16:0.06 molar ratio) by lipid ¢lm hydration
and subsequent extrusion through 0.2 Wm polycar-
bonate ¢lters [36]. When indicated, calcein was in-
corporated as an aqueous marker at a concentration
of 90 mM and/or rhodamine-PE at an amount of
0.1 mol% of total lipid. Freshly thiolated mAb
F10.2 (100 Wg/ml ¢nal concentration) was added to
the liposomes (73.3 Wmol phospholipid/8 ml) and in-
cubated for 1 h and 45 min at room temperature
under constant rotation. The coupling reaction was
terminated by adding 50 Wl of freshly prepared 8 mM
N-ethylmaleimide in HEPES bu¡er (10 mM HEPES;
1 mM EDTA; 135 mM NaCl pH 7.4). Liposomes
were separated from unconjugated mAbs by ultra-
centrifugation (4 runs of 30 min at 60 000Ug) and
stored at 4‡C. As a control in binding and internal-
isation experiments, liposomes with the above men-
tioned composition were used without conjugated
F10.2 mAb.
2.4. Liposome characterisation
Mean particle size was determined by dynamic
light scattering as described before [19]. Mean size
of liposomes was 0.2^0.25 Wm with a polydispersity
index varying from 0.06 to 0.15. Phospholipid con-
centration was determined by the colorimetric meth-
od of Fiske and Subbarow [37]. The amount of con-
jugated IgG on the liposomal surface was determined
with the Bio-Rad DC protein assay kit (Bio-Rad
Laboratories, Hercules, CA, USA) with mouse IgG
as standard. The protein coupling ratios for the dif-
ferent batches of immunoliposomes were in the range
of 2^4 Wg IgG/Wmol phospholipid, which corre-
sponds to approximately 7^15 IgG molecules per lip-
osome.
2.5. Quanti¢cation of the degree of cell binding
IFN-Q-activated BEAS-2B cells were detached
from culture £asks with trypsin/EDTA (Gibco) in
phosphate-bu¡ered salt solution (PBS) for 5 min at
37‡C, pelleted by centrifugation (5 min at 750Ug)
and washed once with immuno£uorescence (IF) bu¡-
er (1% bovine serum albumin and 0.05% sodium
azide in PBS, pH 7.4). A typical washing step in-
volved resuspension of cells into 1 ml of indicated
bu¡er, followed by centrifugation (5 min at
750Ug). Cells (2.5U105 cells for each sample) were
resuspended in 300 Wl of IF bu¡er containing varying
concentrations of control liposomes or F10.2 immu-
noliposomes with entrapped calcein as £uorescent
label. Cells were incubated in the presence of lipo-
somes for 1 h on ice, washed three times with IF
bu¡er to remove unbound liposomes and resus-
pended in 300 Wl IF bu¡er before a sample of 50 Wl
was taken (corresponding to 2.5U104 cells). Samples
were diluted with 150 Wl of 1% Triton X-100 in PBS
and incubated for 15 min at room temperature. Solu-
bilised samples were transferred to a 96-well plate
and the £uorescence intensity of the sample was
measured with a LS-50B luminescence spectrometer
(Perkin Elmer, Beacons¢eld, Bucks, UK) with exci-
tation wavelength set at 490 nm and emission at
520 nm. A reference curve was constructed from cal-
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cein-containing F10.2 immunoliposomes with a
known phospholipid concentration. Background val-
ue was obtained from solubilised cells without prior
incubation with liposomes.
2.6. Cellular internalisation assays
2.6.1. Determination of the amount of cell surface-
bound immunoliposomes as a function of
incubation time
Cell surface-bound F10.2 immunoliposomes were
determined by indirect immuno£uorescence analysis
as described by Suzuki et al. [38]. In short, IFN-Q-
activated BEAS-2B cells (2U105) were detached
from culture £asks using trypsin/EDTA and 2U105
cells were incubated with F10.2 immunoliposomes
(0.5 Wmol phospholipid/ml) in a total volume of
200 Wl keratinocyte medium for 60 min on ice. Cells
were washed twice with ice-cold keratinocyte me-
dium, resuspended into 300 Wl medium and cultured
for 0^3 h at 37‡C. Cells were washed once with IF
bu¡er and incubated with goat anti-mouse IgG £uo-
rescently labelled with phycoerythrin (100 fold di-
luted in IF bu¡er) for 30 min on ice. After washing
twice with IF bu¡er, cells were analysed by £ow
cytometry using a FACscan £ow cytometer (Becton
and Dickinson, Mountain View, CA, USA). The
procedure above was also performed on formalde-
hyde-¢xed cells (cells were ¢xed by incubating with
2% formaldehyde in PBS for 10 min at room temper-
ature).
2.6.2. Determination of intracellular calcein
Detached IFN-Q-stimulated BEAS-2B cells were
incubated with calcein containing F10.2 immunolipo-
somes as described in Section 2.6.1. After two wash-
ing steps with ice-cold keratinocyte medium to re-
move the unbound liposomes, cells were cultured at
37‡C for varying time periods (0^2 h). Hereafter,
cells were incubated for 10 min in citric acid bu¡er
(40 mM citric acid, 120 mM NaCl, pH 3.0), washed
twice with IF bu¡er and analysed by £ow cytometry
using a FACscan £ow cytometer for cell-associated
calcein £uorescence. The mean £uorescence intensity
of 10 000 cells was determined for each sample.
2.6.3. Confocal laser microscopy
In these experiments, the F10.2 immunoliposomes
contained encapsulated calcein (90 mM) as a £uores-
cent aqueous content marker and were labelled with
rhodamine-PE as a liposomal lipid marker. De-
tached, IFN-Q-stimulated BEAS-2B cells were mixed
with F10.2 immunoliposomes in keratinocyte me-
dium on ice as described above (Section 2.6.1). Cells
were washed once with IF bu¡er and once with ker-
atinocyte SFM medium and resuspended into 300 Wl
medium. Subsequently, cells were incubated for vary-
ing time periods (0^60 min) at 37‡C. Thereafter, cells
were either washed twice with IF bu¡er or three
times with citric acid bu¡er (pH 3.0) and once with
IF bu¡er (pH 7.4). Cells were then ¢xed with 2%
formaldehyde in PBS for 1 h on ice and ¢xed to
slides. Fixed cells were analysed for £uorescence us-
ing a laser confocal scanning microscope (Leica TCS
NT Laser confocal scanning microscope, Heidelberg,
Germany). By using ¢lters of 525^550 nm and s 590
nm, rhodamine and calcein £uorescence could be de-
tected separately.
3. Results and discussion
3.1. Quanti¢cation of the degree of cell binding
In a previous study, we have demonstrated that
F10.2 immunoliposomes are able to speci¢cally
bind to di¡erent cell types expressing ICAM-1. The
degree of cell binding appeared to be positively cor-
Fig. 1. E¡ect of liposome concentration on the extent of lipo-
some binding to BEAS-2B cells. INF-Q-stimulated BEAS-2B
cells (1U106 cell/ml) were incubated with F10.2 immunolipo-
somes (b) or with control liposomes (a) for 1 h on ice. After
removal of unbound liposomes, cell-associated calcein £uores-
cence was determined with a £uorometer (n = 3).
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related with the degree of ICAM-1 expression [19]. In
this study, we have quanti¢ed the degree of binding
of F10.2 immunoliposomes to IFN-Q-activated
BEAS-2B cells. The activated epithelial cells were
used as a model system to study targeting e⁄ciency
of F10.2 immunoliposomes to cells with an increased
expression of ICAM-1 as found at sites of in£amma-
tion. The degree of binding of F10.2 immunolipo-
somes to IFN-Q-stimulated BEAS-2B cells was £uo-
rometrically determined by analysing cell-associated
calcein £uorescence after cells were incubated with
calcein-containing F10.2 immunoliposomes for 1 h
on ice. Fig. 1 shows that the absolute amount of
cell-bound immunoliposomes increased with increas-
ing concentrations of calcein-containing F10.2 immu-
noliposomes. Control liposomes with the same lipid
composition but without conjugated F10.2 mAbs
showed a much lower degree of cell binding. From
the calcein £uorescence values, the number of bound
liposomes per cell can be estimated, assuming an
average of 1.5 phospholipid bilayers per liposome
and an average size of 200 nm (Fig. 2). At the highest
concentration of F10.2 immunoliposomes used, ap-
proximately 15 400 liposome particles are estimated
to be bound per cell. However, at such high concen-
trations, liposomes without conjugated F10.2 mAbs
also show considerable cell binding (4200 liposomes
bound per cell), indicating that at high liposome con-
centrations part of the cell binding is mediated by
other interactions than antibody-antigen interaction.
Therefore, the experiments described below were car-
ried out with immunoliposome concentrations of
300^500 nmol phospholipid/ml, at which the binding
ratio of F10.2 immunoliposome versus control lip-
osomes is maximal. At these concentrations, approx-
imately 4000^7000 F10.2 immunoliposomal particles
were binding per cell as compared to only 200^300
particles in case of control liposomes.
3.2. Determination of the amount of cell surface-
bound F10.2 immunoliposomes as a function of
incubation time
Cell surface-bound F10.2 immunoliposomes were
determined by indirect immuno£uorescence analysis
as a function of incubation time at 37‡C. Cells were
incubated with F10.2 immunoliposomes for 1 h on
ice and after removal of unbound particles, the cells
were cultured at 37‡C for varying time periods before
analysis by £ow cytometry. The amount of immuno-
liposomes that could be detected on the surface of
BEAS-2B cells with FITC-conjugated antibodies di-
Fig. 2. E¡ect of liposome concentration on the number of liposomes bound per cell. IFN-Q-stimulated BEAS-2B cells were incubated
with F10.2 immunoliposomes (black bars) or with control liposomes (white bars) essentially as described in Fig. 1. The exact values
of the number of bound liposomes are depicted above each bar. Results of a typical experiment are shown.
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rected against the liposome conjugated antibodies
decreased during prolonged incubation times at
37‡C (Fig. 3). After 1 h incubation at 37‡C, 60% of
the starting amount of cell-bound liposomes had dis-
appeared from the cell surface. Control experiments
using cells ¢xed with formaldehyde prior to liposome
binding did not show any reduction in the amount of
cell-bound F10.2 immunoliposomes, indicating that
the decrease of cell surface-bound immunoliposomes
is not caused by dissociation of immunoliposomes
from the cell surface, but is related to an active cel-
lular process. This ¢nding strongly suggested that
F10.2 immunoliposomes are internalised by BEAS-
2B cells.
3.3. Calcein release from F10.2 immunoliposomes
during cellular internalisation
The next step was to look at the fate of the encap-
sulated £uorescent marker calcein upon internalisa-
tion of F10.2 immunoliposomes by BEAS-2B cells.
Cells were incubated with F10.2 immunoliposomes
for 1 h on ice and unbound particles were washed
away. Hereafter, cell-associated calcein £uorescence
was determined by £ow cytometry, either directly or
after 1 h incubation at 37‡C (Fig. 4). The results
show that after 1 h incubation at 37‡C, the amount
of cell-associated calcein £uoresence had increased in
comparison with the cell-associated calcein £uores-
cence before the 1 h incubation at 37‡C. As calcein
is encapsulated in the liposomes at a quenching
concentration (90 mM), an increase of calcein
£uorescence intensity can be explained as a de-
quenching e¡ect due to calcein release from the
liposomes.
In order to demonstrate that dequenching of cal-
cein £uorescence is caused by the intracellular release
of calcein from internalised F10.2 immunoliposomes
and not merely by extracellular leakage of encapsu-
lated calcein from cell-bound F10.2 immunolipo-
somes, an attempt was made to remove the cell-
bound immunoliposomes by short exposure to low
pH (10 min at pH 3.0). It is described in the litera-
ture that such exposure to low pH will liberate im-
munoliposomes from the cell surface, without dis-
rupting the cell membrane [39,40]. However,
confocal laser microscopic analysis showed us that
acidic exposure of BEAS-2B cells does not result in
the detachment of bound F10.2 immunoliposomes
from the cell surface, but rather in release of calcein
from the cell-bound liposomes (see below, Fig.
6B,D). Nevertheless, acidic treatment of cells can
be used to discriminate between immunoliposome-
encapsulated calcein located at the cell surface from
internalised immunoliposome-encapsulated calcein as
this method completely removes immunoliposome-
Fig. 4. Flow cytometric analysis of cell-associated calcein £uo-
rescence. BEAS-2B cells were incubated with F10.2 immuno-
liposomes (500 nmol phospholipid/ml) on ice and unbound lipo-
somes were removed. Thereafter cells were either directly
analysed for associated calcein £uorescence (solid line) or after
1 h incubation at 37‡C (dotted line). Auto£uorescence of
BEAS-2B cells is also illustrated (in black).
Fig. 3. Determination of cell surface-bound F10.2 immunolipo-
somes on BEAS-2B cells during prolonged incubation periods
at 37‡C. Intact (b) or formaldehyde-¢xed (a) cells (1U106/ml)
were incubated with F10.2 immunoliposomes (500 nmol phos-
pholipid/ml) for 1 h on ice, washed twice with keratinocyte-
SFM medium (without serum), and then cultured at 37‡C in
SFM medium for the indicated time periods. Subsequently, cells
were labelled with phycoerythrin-conjugated goat anti-mouse
mAbs and analysed by £ow cytometry (n = 4).
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encapsulated calcein £uorescence located at the cell
surface. The acid treatment method was used to de-
termine the degree of intracellular calcein-£uores-
cence as a function of incubation time at 37‡C
(Fig. 5). For this experiment, cells were pre-incu-
bated with F10.2 immunoliposomes for 1 h on ice
to load cells with immunoliposomes. Hereafter, cells
were cultured at 37‡C for varying time periods fol-
lowed by acid treatment to remove the calcein from
immunoliposomes located at the cell surface. Fig. 5
shows that the amount of intracellular calcein £uo-
rescence increases at increasing incubation times at
37‡C. The observation that cell-associated calcein
£uorescence decreases after 2 h incubation at 37‡C
may be caused by intracellular compounds that are
able to quench the calcein £uorescence. For example,
Fe2 ions present in the cell will quench calcein £uo-
rescence [41]. However, the possibility that calcein
that is released intracellularly will subsequently leak
out of the cells cannot be excluded.
3.4. Confocal laser microscopic analysis of F10.2
immunoliposome internalisation and subsequent
intracellular release of calcein
We have further analysed the process of liposome
internalisation by confocal laser microscopy (Fig. 6).
Cells were incubated with F10.2 immunoliposomes
containing two £uorescent markers; rhodamine-PE
as a lipid marker and encapsulated calcein as an
aqueous marker. After incubation for 1 h at 4‡C,
both calcein £uorescence and rhodamine £uorescence
were observed associated with the cell membrane
(Fig. 6A). By superimposing two pictures taken with
two di¡erent ¢lter settings (525^550 nm and s 590
nm), it can be seen that the liposomal membrane
marker rhodamine-PE and the aqueous marker cal-
cein are co-localised as visualised by the yellow £uo-
rescence. Calcein £uorescence, but not rhodamine
£uorescence, could be removed from the cell surface
by exposing the cells for 10 min to pH 3.0 (Fig. 6B).
C
Fig. 6. Confocal laser microscopic analysis of the internalisation of F10.2 immunoliposomes containing calcein and rhodamine-PE as
£uorescent tracers into IFN-Q-activated BEAS-2B cells. BEAS-2B cells were incubated with F10.2 immunoliposomes either for 1 h on
ice (A,B) or for 1 h on ice and subsequently for 1 h at 37‡C (C,D). Thereafter, cells were either directly analysed by confocal laser
microscopy (A,C) or exposed to citric acid bu¡er (pH 3.0) for 10 min (B,D) before analysis. Used ¢lter settings were 525^550 nm
(green £uorescence) and s 590 nm (red £uorescence). Superimposed pictures of both ¢lter settings are also illustrated.
Fig. 5. Flow cytometric analysis of immunoliposome-encapsulated calcein internalisation into BEAS-2B cells. Cells (1U106 cells/ml)
were incubated with F10.2 immunoliposomes at a concentration of 500 nmol phospholipid/ml for 1 h on ice, washed twice with kera-
tinocyte-SFM medium and incubated at 37‡C in SFM medium for the indicated time periods. Thereafter, cells were exposed to acidic
condition (citric acid bu¡er, pH 3.0) for 10 min and washed twice with IF bu¡er before £ow cytometric analysis (n = 2).
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Fig. 6 (continued)
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Incubation of cells with surface-bound F10.2 immu-
noliposomes at 37‡C resulted in the appearance of
bright £uorescent vacuoles in the cell interior, besides
the cell membrane-associated £uorescence (Fig. 6C).
Exposure to low pH showed the disappearance of
surface-bound calcein £uorescence, but not of calcein
located inside intracellular vacuoles (Fig. 6D), con-
¢rming the evidence that immunoliposomes, together
with the encapsulated calcein, are internalised.
3.5. Overall conclusions
Taking all results together, we can conclude that
immunoliposomes targeted to ICAM-1 on IFN-Q-ac-
tivated human bronchial epithelial cells are able to
bind to these cells. Depending on the concentration
of immunoliposomes added, 1^14 nmol liposomal
phospholipid appeared to bind per 106 BEAS-2B
cells after 1 h incubation on ice, which corresponds
to 680^15 400 particles bound per cell. Furthermore,
we studied whether ICAM-1-directed immunolipo-
somes are internalised by BEAS-2B cells. Little is
known about the internalisation characteristics of
ICAM-1 molecules. ICAM-1 is utilised as a target
receptor by the major group of human rhinoviruses.
Binding to ICAM-1 results in receptor-mediated en-
docytosis of the bound virus particles [42]. On the
other hand, internalisation of monoclonal antibodies
directed against ICAM-1 (mAb RR1/1) on human
umbilical vein endothelial cells could not be detected
[43]. In this study, it was observed that F10.2 immu-
noliposomes are rapidly internalised after speci¢c
binding to ICAM-1 expressing BEAS-2B cells. After
1 h incubation at 37‡C, 60% of the surface-bound
immunoliposomes were internalised. These ¢ndings
have implications for the development of drug-tar-
geting strategies to interfere in in£ammatory proc-
esses. The rapid and extensive internalisation of
ICAM-1-targeted liposomes make them suitable car-
riers for the intracellular delivery of anti-in£amma-
tory drugs. Also, ICAM-1-directed immunolipo-
somes may be used to selectively deliver antisense
oligonucleotides to endothelial and epithelial cells
to down-regulate adhesion molecule expression at
sites of in£ammation. As ICAM-1 is involved in
the migration of in£ammatory cells into in£amed
tissues, down-regulation of ICAM-1 expression by
antisense oligonucleotides will inhibit the migration
of immune cells into in£amed tissues [44], thereby
inhibiting the in£ammatory response [45,46]. How-
ever, it should be realised that the liposomal system
needs to be further optimised before application in
vivo. The immunoliposome composition used in the
present in vitro study may not be optimal in vivo.
Also, the presence of whole antibody molecules ex-
posed on the liposome surface may give problems
related to immunogenicity when applied repeatedly
in vivo [47,48]. In addition, circulating time after
intravenous injection might be too short to allow
e⁄cient interaction with target epitopes.
Although it was observed that calcein is released
from the immunoliposomes upon internalisation, this
does not guarantee that other encapsulated com-
pounds will become available to intracellular targets
after internalisation of liposomes. The confocal mi-
croscopic ¢ndings strongly suggest that internalisa-
tion occurs via receptor-mediated endocytosis. A
large amount of endocytosed liposomes will eventu-
ally end up in lysosomal, degradative compartments
[22,23,49]. We are currently exploring ways to escape
lysosomal degradation by incorporating pH-depend-
ent fusogenic properties into the immunoliposomal
carrier, in order to promote delivery over the endo-
somal membrane and thereby improving the thera-
peutic availability of the encapsulated compound
after cellular internalisation.
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